TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Four-week Open-trial Extension TNS for ADHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* male and female children ages 8-12 with DSM-5 ADHD, and current presentation, as determined by KSADS and clinical interview~* participated in a previous randomized, double-blind, sham-controlled trial of TNS for ADHD, and randomized to the sham condition.~* parents able and willing to monitor proper use of the TNS device and complete all required rating scales~* parent and participants able to compete study rating scales and other measures in English~Exclusion Criteria:~* currently requiring any medication with CNS effects

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Active TNS (Type: EXPERIMENTAL): Participants who previously underwent screening and determination of eligibility in a double-blind sham-controlled trial of TNS for ADHD, and randomized to sham, will be offered upon unblinding at the end of the 5-week controlled trial to receive 4-weeks open treatment with the active TNS condition.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Diclofenac Gel for Breakthrough Pain and the Neuropathic Components of Pain in Knee Osteoarthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 20-75~* Unilateral or bilateral knee osteoarthritis (OA), confirmed radiographically.~* Patients taking oral non-steroidal anti-inflammatory drugs (NSAIDs) in the amount and schedule prior to the breakthrough period will be permitted.~Exclusion Criteria:~* Patients with clinical history of anterior cruciate ligament (ACL) involvement.~* Patients on tricyclic antidepressants or anticonvulsants (neuropathic medications)~* History of ulcers or gastrointestinal (GI) bleeding~* Coagulation disorders~* Hypersensitivity to Aspirin or NSAIDS~* Congestive Heart Failure and Edema~* Advanced renal disease~* Aspirin triad~* Pregnant women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Diclofenac gel (Type: OTHER): Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with chronic kidney disease and in dialysis with identified antibodies against at least two HLA antigens of which at least one is 3000 MFI or more as measured by SAB assay on at least two occasions.~Exclusion Criteria:~* Prior malignancy within 2 years excluding adequately treated basal cell or squamous cell skin cancer, cervical carcinoma in situ and prostate cancer Gleason \<6 and prostate-specific antigen (PSA) \<10 ng/mL.~* Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody and human immunodeficiency virus (HIV~* Clinical signs of ongoing infectious disease.~* Severe other conditions requiring treatment and close monitoring, e.g. cardiac failure \> New York Heart Association (NYHA) grade 3, unstable coronary disease or oxygen dependent chronic obstructive pulmonary disease (COPD)~* History of any other clinically significant disease or disorder which, in the opinion of the investigator, may either put the patient at increased risk because of participation in the study, or influence the results or the patient's ability to participate in the study~* Hypogammaglobulinemia defined as any values of P-total IgG less than 3 g/L~* History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to IdeS (e. g streptokinase and/or staphylokinase)~* Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within 4 months of the first administration of investigational product in this study. Patients consented and screened but not dosed in previous studies are not excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous IdeS (Type: EXPERIMENTAL): One or two doses of IdeS in ascending doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Escitalopram Doses up to 50mg in Treatment of MDD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent will be obtained from each patient~* aged 18 to 65 inc~* suffering from MDD as defined by DSM IV~* have been taking citalopram in a dose of at least 20mg for at least six weeks~* an inadequate response -- defined as failure to achieve a MADRS score of \<12~Exclusion Criteria:~* Significant other psychiatric disorder which would interfere with trial assessments. Co-morbid generalized anxiety disorder (GAD) and panic will be permitted where MDD is considered the primary diagnosis .~* history of mania or bipolar disorder~* Known contraindication for the use of citalopram or escitalopram.~* Significant bleeding disorder~* Prominent suicidal ideation (score more than 4 in the MADRS suicidal thoughts item)~* Alcohol or substance dependence in the past 6 months~* Major physical illness~* Significant liver or renal function abnormality~* Significant ECG abnormalities~* Pregnant or lactating females~* Inadequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): Active escitalopram

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Emodepside in Adolescents and Adults Infected With Hookworm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults aged between 12 and 60 years;~* Written and signed informed consent;~* Was examined by a study physician before treatment;~* Provided two stool samples at baseline;~* Hookworm EPG \> 48 and at least two Kato-Katz thick smears slides with more than one hookworm eggs.~Exclusion Criteria:~* Pregnant or lactating and/or planning to become pregnant within three months after drug treatment;~* Type 1 and/or 2 diabetes;~* Psychiatric disorders;~* History of ophthalmological conditions;~* Presence or history of major systemic or chronic illnesses, as assessed by a medical doctor, during initial clinical assessment;~* Suffers from severe anaemia (Hb \< 80 g/l);~* Received anthelminthic treatment within past four weeks;~* Attending other clinical trials during the study;~* Received strong CYP3A4 inducers or inhibitors as well as concomitant treatments that are relevant substrate for CYP3A4 such as clarithromycin, erythromycin and rifampicin;~* Received strong P-gp inhibitors as well as concomitant treatments that are relevant substrates for P-gp such as clotrimazole and ritonavir.~* Participated in stage I trials of this protocol

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Emodepside 30 mg (Type: EXPERIMENTAL): None
- Albendazole 400 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neurocognitive and Neurobiological Improvement in ADHD Children by Modification of Dietary Protein

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ADHD diagnosed 12 months before~* no take medication~* BMI above the 25th percentile~* Wiesel score between 80 and 100 (about 120)~* Patients who agree to participate and whose guardians signed the informed consent form~Exclusion Criteria:~* eating disorders~* psychosis, bipolar disorder or depression~* kidney or liver failure~* diabetes~* diuretic or cortisone treatment~* haematological problems~* suprarenal diseases~* cancer~* Brain injury~* Cardiovascular or arrhythmia problems

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- BP22042013 (Type: EXPERIMENTAL): This group of patients receive 2.000 kilocalories diet(60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
- Low carbohydrate Diet (Type: EXPERIMENTAL): the second group of patients receive diet of 2.000 Kilo calories without rapidly absorbed carbohydrates and without proteins supplements

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cleancision IntRaoperative Contamination prEvention Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 and older~* BMI 15-45, inclusive~* Colorectal surgery patient, planned resection~* Incision length meets labeling requirements~* Written informed consent using the governing IRB approved form~Exclusion Criteria:~* Patients with a pre-existing stoma~* Patients undergoing emergent colorectal surgery~* Known history of contact hypersensitivity or allergy to device materials~* Prior laparotomy or abdominal surgery within a timeframe that may present a safety risk or compromise study results~* Active infection, sepsis or systemic antibiotic therapy within timeframe that may impact safety or study results~* Active participation in any other clinical study of an experimental drug or device that may impact safety or study results~* Postsurgical life expectancy is less than the study follow up period~* Subject is pregnant or lactating~* Subject is under incarceration~* Subject considered to be inoperable following exploratory surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): All study subjects will be treated using the CleanCision device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥18 years old hospitalized patients with bacteremia from any source with isolation of an enterobacteria in blood cultures.~2. Active empiric treatment with antipseudomonal betalactamic at 48 hours from the symptoms of sepsis and the blood culture.The patient could have received any other type of antibiotic therapy up to 24 hours after blood extraction.~3. Microorganism susceptible at least one treatment from the experimental arm.~4. Patients with intravenous treatment at least 3 days from the randomization o 5 days from the initial blood culture.~5. Patients to sign the informed consent form.~Exclusion Criteria:~1. Palliative care or life expectance \< 90 days.~2. Pregnancy or lactation period.~3. To isolate the Extended-spectrum β-lactamases producing Enterobacteriaceae~4. Late randomization \>48 hours after the enterobacteriaceae blood culture´s identification~5. Severe neutropenic (\< 500 céls/mm3) at the randomization.~6. Treatment of infection \> 28 days (endocarditis and osteomyelitis) or meningitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Antipseudomonal beta-lactam antibiotic (Type: EXPERIMENTAL): 1. Ampicillin 2g IV/6h~2. Trimethoprim/sulfamethoxazole 160/800 mg IV/8 -12h~3. Cefuroxime 750-1000 mg IV/8h~4. Cefotaxime 1-2g IV/8h ó ceftriaxone 1 g/12-24h~5. Amoxicillin/clavulanate 1000/125 mg IV/8h~6. Ciprofloxacin 400 mg IV/12h~7. Ertapenem 1-2g/24h.
- De-escalation(short-spectrum antibiotic) (Type: ACTIVE_COMPARATOR): * Piperacillin/tazobactam 4/0.5 g IV/8h~* Meropenem 1-2 g IV/8h~* Imipenem 0.5 g IV/6h - 1g IV/6h~* Aztreonam 1-2 g IV/8h~* Ceftazidime 1-2 g IV/8h~* Cefepime 2 g IV/8-12h

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post Operative Sore Throat and Dexamethasone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients undergoing outpatient laparoscopic gynecologic surgery~* ASA PS I and II~* Age between 18 and 64 years~* Fluent in English~Exclusion Criteria:~* History of recent respiratory tract infection~* Pregnancy, breastfeeding~* Current treatment with analgesics~* Current use of corticosteroids~* Anticipated difficult intubation~* Risk factors for post-operative aspiration

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 Placebo (Type: PLACEBO_COMPARATOR): Normal saline 100ml (placebo) administered as a intravenous infusion 30 minutes prior to surgery.
- Group 2: Dexamethasone 0.05mg/kg (Type: ACTIVE_COMPARATOR): Dexamethasone 0.05 mg/kg administered in 100 ml of sterile saline solution prior to surgery
- Group 3:Dexamethasone 0.1mg/kg (Type: ACTIVE_COMPARATOR): Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~All of the following:~* Patient must have non-M3 AML or MDS~* An adverse risk karyotype defined by:~  * Complex karyotype by cytogenetics, or~ * Deletion of all or part of chromosome 5, 7, 12, or 17 defined by FISH or cytogenetics, or~ * Somatic TP53 mutation~All of the following:~1. Patient must have an ECOG performance status ≤ 2.~2. Patient must have \>10% disease burden measured by cytomorphology, flow cytometry, or cytogenetics.~3. Patient must have peripheral white blood cell count \< 50,000/mcl.~4. Patient must have adequate organ function, defined as:~   1. Total bilirubin \< 1.5 x ULN~  2. AST/ALT \< 2.5 x ULN~  3. Serum creatinine \< 2.0 x ULN~5. Patient must have undergone ≤ 2 cycles of prior hypomethylating agent (decitabine or azacitidine).~6. Patient must be enrolled in HRPO# 201011766 (Tissue Acquisition for Analysis of Genetic Progression Factors in Hematologic Diseases).~7. Patient must be \> 18 years of age.~8. Patient must be able to understand and willing to sign an IRB-approved written informed consent document.~Exclusion Criteria:~* Patient must not be pregnant or nursing~* Patient must not have acute promyelocytic leukemia or t(15;17) observed by FISH.~* Patient must not have known central nervous system (CNS) leukemia~* Patient must not have a history of positive human immunodeficiency virus (HIV) serology~* Patient must not have a history of positive hepatitis C serology~* Patient must not have undergone prior allogeneic stem cell transplant~* Patient must not have any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, ongoing or active graft-versus-host disease (GVHD), congestive heart failure of New York Heart Association (NYHA) class 3 or 4, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements~* Patient must not have had radiation therapy within 14 days of enrollment~* Patient must not have received any chemotherapy within 21 days of enrollment and any acute treatment-related toxicities must have returned to baseline. Patients may be receiving hydrea at time of enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decitabine (Type: EXPERIMENTAL): Patients receive decitabine IV over 1 hour on days 1-10 of a 28-day cycle. Treatment continues for 2 cycles. Patients then receive decitabine IV over 1 hour on days 1-10, 1-5, or 1-3 (depending on response). Treatment continues in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects with Onchocerca volvulus infection~Exclusion Criteria:~* Pregnant or breast feeding women; coincidental loiasis

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Moxidectin (Type: EXPERIMENTAL): Moxidectin 8mg
- Ivermectin (Type: ACTIVE_COMPARATOR): Ivermectin 150 mcg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Imatinib - resistant or - intolerant Philadelphia chromosome-positive CML in blast crisis, accelerated or chronic phase~* Males or females ≥ 18 years of age~Exclusion Criteria:~* Impaired cardiac function~* Acute or chronic liver or renal disease~* Use of therapeutic coumadin~* Central nervous system (CNS) infiltration~Additional protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMN107 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* At least 65 years of age who are eligible for the study vaccines;~* Who have given written informed consent at the time of enrollment);~* Those who are available for all the visits scheduled in the study;~* Subjects In good health as determined by medical history, physical examination and clinical judgment of the investigator~Exclusion Criteria:~* History of egg allergy~* History of influenza vaccination in previous 6 months~* History of any pneumococcal vaccination~* Documented S. pneumonia infection in the previous 5 years~* Chemotherapy for malignancy within the past 30 days~* High-dose systemic steroid (prednisone ≥0.5 mg/kg/day) in the past 30 days~* Receipt of blood product within 6 months before enrollment~* Significant acute or chronic infection within the previous 7 days or fever within the previous day~* Any serious chronic or progressive disease~* Any condition that might interfere with the study results.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Fluad alone (Type: ACTIVE_COMPARATOR): 56 Fluad recipients: one vaccine injection administered on Day 0
- Fluad and PPV23 on the different arms (Type: ACTIVE_COMPARATOR): 56 concomitant Fluad-PPV23 recipients on the different arms: one dose of each vaccine administered on Day 0
- Fluad and PPV23 on the same arm (Type: ACTIVE_COMPARATOR): 56 concomitant Fluad-PPV23 recipients on the same arm with 1 inch distance: one dose of each vaccine administered on Day 0
- PPV23 alone (Type: ACTIVE_COMPARATOR): 56 PPV23 recipients: one vaccine injection administered on Day 0

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete